Kornimate/medical-research-clean huggingface dataset:
low -vs- high-frequency repetitive tms of the right dorsolateral prefrontal cortex in ptsd

Conditions: PTSD - Post Traumatic Stress Disorder

Summary: this is a randomized placebo/sham controlled, double-blind study investigating the efficacy of high- and low-frequency rtms applied to the right dlpfc at either 1 hz, 10 hz, or sham rtms as compared to an oasis treatment as usual group for the treatment of ptsd symptoms.

the study will be carried out within the overcoming adversity and stress injury support (oasis) program administered by naval medical center san diego (nmsd). oasis is a residential treatment program developed for active duty service members diagnosed with combat related ptsd. oasis is a 9 week program in which cohorts of 10 patients undergo a variety of therapeutic activities with a focus on cognitive processing therapy (cpt) of combat trauma conducted in both group and individual formats. subjects who qualify will be assigned by block randomization to one of four arms: 1. 1 hz rtms of the right dorsolateral prefrontal cortex 2. 10 hz rtms of the right dorsolateral prefrontal cortex 3. sham rtms of the right dorsolateral prefrontal cortex 4. oasis treatment as usual treatment will be administered in 10 daily sessions, conducted on weekdays, for 2 consecutive weeks. .

Eligibility criteria:
inclusion criteria: participant in the oasis program willing and able to give informed consent diagnosis of post-traumatic stress disorder as determined by the caps caps score of at least 50 males or females between 18-65 years of age exclusion criteria: current primary axis i disorder including schizophrenia, bipolar disorder type i, active substance use patients with severe or unstable medical conditions, which in the opinion of the investigator would interfere with their progress or safety ect treatment within the last 30 days patients with neurological disorder leading to increased intracranial pressure participation in other interventional treatment protocols (participants of monitoring/observational studies can be included)

Keywords: rtms - repetitive transcranial magnetic stimulation caps - clinician administered ptsd scale
drug-drug interaction study with aricept® (donepezil)

Conditions: Alzheimer Disease

Summary: the purpose of this study is to find out if the plasma concentration of donepezil is changed when bms-708163 is administered at the same time


Eligibility criteria:
inclusion criteria: * healthy men and postmenopausal women exclusion criteria: * medical history and concurrent diseases * gastrointestinal disease * gastrointestinal bleeding disorders * history of peptic ulcer disease * history of cholecystectomy * history of seizure disorder * history of asthma * history of chronic obstructive pulmonary disease * history of cardiac conduction abnormalities, including but not limited to "sick sinus syndrome" and those with unexplained syncopal episodes * inability to tolerate oral medication * inability to be venipunctured and/or tolerate venous access
analysis of microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease

Conditions: Inflammatory Bowel Diseases; Irritable Bowel Syndrome

Summary: inflammatory bowel disease (ibd) is characterized by severe inflammation of the small bowel and/or the colon leading to recurrent diarrhea and abdominal pain. irritable bowel syndrome with diarrhea (ibs-d) is characterized by abdominal pain or discomfort, gas, loose and frequent stools. butyrate has shown anti-inflammatory and regenerative properties, providing symptomatic relief when orally supplemented in patients suffering from various colonic diseases. the investigator proposes to investigate the effect of a microencapsulated form of sodium butyrate on the fecal microbiota of patients with ibd and ibs-d.

the ibdmicro is an interventional, randomized, double-blind, placebo-controlled study. a novel oral formulation of butyrate contained in a lipophilic microcapsule, that provides extensive capacity for intestinal diffusion and facilitates slow release of the active ingredient will be used ("butyrose" produced by sila srl, italy). a proof-of-concept study has been already published in this context, and preliminary data showed that butyrate administration was able to change the gut microbiota of patients with ibd and ibs-d after 12 weeks of treatment, in association with the changes of intestinal inflammation indexes (fecal calprotectin). in keeping, investigators will assess the microbiota before and after the butyrate administration. also, clinical data will be collected by using validated disease-specific questionnaires (rome iv and clinical indexes for ibd). quality of life will be also recorded. the analysis of intestinal microbiota will be carried out by collecting a fecal sample and analyzed with metagenomics techniques.

Eligibility criteria:
inclusion criteria: * patients with histologically confirmed diagnosis of crohn disease (cd) or ulcerative colitis (uc) in the last 6 months and undergoing followup colonoscopy. exclusion criteria: * (a) prior proctocolectomy; * (b) presence of ibd extraintestinal manifestation; * (c) treatment with antibiotics in the last 60 days; * (d) extensive surgical resection; * (e) presence of stoma.

Keywords: ibd microbiota butyrate ibs
colorectal cancer awareness in turkey

Conditions: Colorectal Cancer

Summary: colorectal cancer is among the most common types of cancer worldwide. population-based screening programs for breast, cervical, and colorectal cancer have been introduced as part of cancer control in many high-income countries. population-based cancer screening programs do not exist in most low- and middle-income countries. there are some studies that report the awareness of colorectal cancer in turkey.

colorectal cancer is the third most common type of cancer in both men and women. according to world health organization data, in 2012, 694 thousand people were thought to be due to colorectal cancer and this number increased to 862 thousand people in 2018. especially in most low- and middle-income countries where cancers are mainly detected through very-late-stage symptoms and many are not reported. recent researches may lead to new approaches to early detection and treatment using improved awareness of the symptomatic disease and population-based screening of asymptomatic people. the increasing of colorectal cancer awareness could help early detection of colorectal cancers. in this study, the investigators aimed to determine the level of awareness of colorectal cancer and knowledge about colorectal cancer screenings in patients who applied to general surgery outpatients clinic where a colorectal cancer diagnosis was most frequently diagnosed.

Eligibility criteria:
inclusion criteria: * patients who apply to the general surgery outpatients clinic exclusion criteria: * younger than 18 years old * older than 80 years old * mental retardation or other mental illness * refusing to join the study

Keywords: colorectal cancer awareness screening
population pharmacokinetics of propafenone and propranolol in children patients

Conditions: Arrhythmia

Summary: the use of propafenone and propranolol in children during clinical treatment was depending mostly on experience. besides, there was no recommended dose for children in drug instruction. therefore, the investigators' aim is to study the pharmacokinetics and pharmacodynamics in children.


Eligibility criteria:
inclusion criteria: * patients aged ≤18years. parental written consent to participate in the study. patients treat with propafenone and propranolol exclusion criteria: * patients can not complete the research; abnormal hepatic and renal function; patient is allergic to propafenone; there are conditions that researchers do not consider it appropriate to join the research.
vertical bone gain and neurosensory affection in computer guided vs conventional sandwich osteotomy

Conditions: Bone Loss

Summary: the aim of this study was to assess the efficiency of the computer-guided interpositional sandwich osteotomy for the vertical bone gain and effects on vital structures (inferior dental nerve bundle) compared to free hand interpositional osteotomies.

in this research a full digital sandwich osteotomy protocol was conducted to be compared with the conventional protocol. the investigators were seeking to determine the significance of using surgical computer software in sandwich interpositional bone grafting at atrophied posterior mandibles and how efficiently can it affect this technique.

Eligibility criteria:
inclusion criteria: * • edentulous posterior mandibular ridge with vertical loss of alveolar bone with remaining bone height (4-7 mm) above the mandibular canal * good oral hygiene * highly motivated patients * patients seeking fixed prosthesis at posterior mandibular region. * patients willing for a surgical procedures follow-up with an informed consent * age range 20-65 years exclusion criteria: * • smokers * individuals with dentulous posterior mandible ridge * medically compromised patients * patients with local pathosis at the surgical area suggested * previously subjected to reconstructive procedures of the posterior mandible
effectiveness of neuromuscular exercise in patellofemoral pain syndrome

Conditions: Patellofemoral Pain Syndrome

Summary: the aim of the study is to investigate the effects of a neuromuscular exercise program on strength, balance, sleep quality and functionality in individuals with patellofemoral pain syndrome.

the research is planned as a quantitative study. classical knee exercises will be given to 25 individuals in the control group of the study. an exercise program consisting of neuromuscular exercises will be applied to 25 individuals in the intervention group. in data collection, strength and balance measurements will be measured face to face by a physiotherapist, and the scales to be made through a survey will be sent to the patients online and they will be asked to fill them out. the scales and forms to be used are as follows: 1.kujala patellofemoral score scale 2.lysholm knee scoring scale 3.international physical activity survey 4.pittsburgh sleep quality index 5.y balance test 6.30 seconds sit and stand test applied scales will be done by the physiotherapist. the surveys will be uploaded to the google forms database and the participants will be contacted via e-mail or mobile phone applications (such as whatsapp, telegram) to participate. they will first be asked to fill out the surveys before starting the exercise program and they will be asked to apply the exercise program. it will be explained as follows. exercises will be planned 3 times a week and for 12 weeks. participants will be asked to participate in the survey again after completing the exercise program.

Eligibility criteria:
inclusion criteria: * volunteering to participate in the study. * not under 30 years of age and not over 60 years of age. * having patellofemoral pain syndrome. * not having a physical disability. * not having undergone any knee-related surgery. * having access to a computer/tablet/phone and the internet. exclusion criteria: * not accepting the voluntary consent form. * being under 30 years of age and over 60 years of age. * having undergone any knee-related surgery. * having cognitive, mental or psychological problems. * having impaired vision or hearing. * having a physical condition that causes significant loss of function.
sustiva levels with use of a gel capsule

Conditions: HIV; HIV Infections

Summary: we are studying if putting a gel capsule over a standard hiv drug changes the ability of the body to absorb the drug. this is important because we want to be able to study new hiv drugs against the most common drugs used today and the most common is sustiva, which is also called efavirenz. we will give you sustiva every day for 5 days and draw blood to see how much is absorbed. then we will give you sustiva that has a gel capsule over it for 5 days and we will draw blood to see how much is absorbed.


Eligibility criteria:
inclusion criteria: * hiv-negative, proven by elisa * age: ≥ 18 years old exclusion criteria: * psychiatric or psychological illness that would make adherence to protocol procedures unlikely.

Keywords: efavirenz sustiva pharmacokinetics
objective sepsis identification tool to study sepsis epidemiology

Conditions: Sepsis

Summary: globally, sepsis affects an estimated 31.5 million people and accounts for 5.3 million deaths each year. this calculation is based on data from western high income countries only. the purpose of this study is to develop an objective sepsis identification tool using electronic health records to study the epidemiology of sepsis in hong kong.

globally, sepsis affects an estimated 31.5 million people and accounts for 5.3 million deaths each year. the incidence of sepsis is increasing and is now a more common cause for hospital admission than acute myocardial infarction and stroke. however this apparent improvement in sepsis outcomes may also be due to changes in definition and reporting of sepsis. the latest sepsis-3 definition outlines sepsis as life-threatening organ dysfunction due to dysregulated host response to infection. trends on sepsis incidence and outcome were based on previous definitions of sepsis. furthermore, changes in coding practices and documentation for hospital claims may cause misleading changes in incidence and outcomes. electronic health record clinical data provides more reliable data on sepsis epidemiology than diagnostic coding accounts for. our understanding of sepsis epidemiology is based on studies from high income western countries. even within these countries, health expenditure and resources vary which may affect sepsis outcomes. current data on the burden of sepsis from the rest of the world is insufficient. hong kong is well poised to provide these lacking data on the epidemiology of sepsis. more than 90% of inpatient care is provided by the public healthcare system and would be captured by the electronic clinical management system. the purpose of this study is to develop an objective sepsis identification tool using electronic health records to study the epidemiology of sepsis in hong kong.

Eligibility criteria:
inclusion criteria: * january 2018 to february 2018 adult inpatients at prince of wales hospital * 1st microbiological culture tests during hospital admission exclusion criteria: * duplicated microbiological sampling * missing values for sequential organ failure assessment score calculation * microbiological tests were for screening only (methicillin-resistant staphylococcus aureus swabs, vancomycin resistant enterococci rectal swab) * antibiotics not started 2 days before or after first microbiological sampling * antibiotics duration less than 4 days unless death * not given antibiotics on discharge if given less than 4 days antibiotics in hospital
comparison of metal and plastic stents for preoperative biliary decompression

Conditions: Obstructive Jaundice; Pancreatic Cancer

Summary: covered self expandable metal stents (csems) are three times larger in diameter than 10 fr plastic stents. when compared to plastic stents, randomized trials have shown longer patency and fewer stent-related complications for csems. the investigators hypothesize that placement of csems would be a better treatment option for preoperative biliary decompression in patients with pancreatic cancer.

covered self expandable metal stents (csems) are three times larger in diameter than 10 fr plastic stents. when compared to plastic stents, randomized trials have shown longer patency and fewer stent-related complications for csems. the investigators hypothesize that placement of csems would be a better treatment option for preoperative biliary decompression in patients with pancreatic cancer as there will be better drainage of the obstructed biliary system with fewer adverse events.

Eligibility criteria:
inclusion criteria: * patients with pancreatic cancer and mass in the head of pancreas causing jaundice. * patients 19 yrs of age and older * serum bilirubin \> 2mg/dl * ct: no evidence of distant metastasis or local vascular invasion (tumor surrounding portal or mesenteric vessels for more than 180 degrees of their circumference or an irregular vessel margin). exclusion criteria: * karnofsky score \< 60 * prior (ercp or ptc) attempts at biliary decompression for the same indication * tumor-related gastric outlet obstruction (vomiting and oral intake of \< 1l/day) * ongoing or planned neoadjuvant therapy * cholangitis at presentation or coagulopathy needing reversal medication * post-surgical anatomy * multiple extra-hepatic biliary strictures or concomitant stricture in liver hilum * failed ercp's (definition: inability to deploy a biliary stent thereby requiring a ptc or surgery).

Keywords: pancreatic cancer obstructive jaundice obstructive jaundice secondary to pancreatic cancer
baricitinib therapy in covid-19

Conditions: COVID; Pneumonia

Summary: retrospective study on the efficacy of baricitinib in 12 covid-19 patients with moderate pneumonia.

baricitinib, an anti-janus kinase inhibitor (anti-jak) acting against jak1 and jak2 that inhibits jak1- and jak2-mediated cytokine release, was recently described using benevolentai's proprietary artificial intelligence-derived knowledge graph, as an agent that reduces the endocytosis into target cells, and to inhibit the entry. based on its potential action on inhibition of sars-cov-2 entry, and on its known effects on reduction of cytokine release, baricitinib therapy was proposed in patients with moderate pneumonia to explore: the safety of this drug combined with antiviral (lopinavir-ritonavir) in covid-19; as second outcome, to evaluate the impact of baricitinib in terms of clinical, laboratory, respiratory parameters, and reduction of icu admission. baricitinib was combined with antivirals because it does not interact with them due to its prevalent renal elimination.

Eligibility criteria:
inclusion criteria: * sars-co-v2 positivitity to the nasal-swab by reverse-transcriptase-polymerase chain- reaction (rt-pcr) assay tested by the local diagnostic laboratory * age \>18 and \<85 years * presence of at least 3 of the following symptoms as present fever, cough, myalgia, fatigue. * presence of radiological findings of pneumonia assessed by chest radiograph, computed tomography, or pulmonary ultrasound. * peripheral capillary oxygen saturation (spo2) \> 92% on room air at screening * pao2/fio2 \>100-300 mmhg at arterial blood gas analysis. exclusion criteria: * age \ 85 * history of thrombophlebitis * latent tuberculosis infection (based on the positivity to quantiferon plus positivity, qiagen, germany) * pregnancy and lactation * history of malignancies over the previous 5 years, current diagnosis of malignancy * inability or unwillingness to sign a written consent. * transaminases values 4-fold higher than the upper normal limit. * hbv and hcv positivity. * current herpes zoster infection. * evidence of concomitant bacterial infections.

Keywords: covid-19 baricitinib moderate disease
safety, pharmacokinetics (pk) and tolerability study of a novel drug for treatment of bacterial infections

Conditions: Gram-negative Bacterial Infection

Summary: the purpose of this study is to evaluate the safety, tolerability and pharmacokinetic profile of an antibacterial compound for treatment of hospital acquired gram negative infection.

single-center, randomized, placebo-controlled, double-blind study to determine the safety, tolerability and pharmacokinetic profile of compound in single and multiple doses in young healthy males.

Eligibility criteria:
inclusion criteria: * young healthy males, 18-45 years (inclusive) of age * healthy as judged by a responsible physician with no clinically significant abnormality * surgically sterile or agrees to abstain from sexual intercourse with a female partner or agrees to use a condom and spermicide during sexual intercourse with a female partner who uses another form of contraception * body weight above 50 kg (body mass index between 19 and 30 kg/m2) * non-smokers * willing and able to comply with study instructions and commit to all follow-up visits * ability to understand, agree to and sign the study informed consent form (icf) exclusion criteria: * history of serious adverse reactions or hypersensitivity to any drug; or who have a known allergy to any of the test product(s) or any components in the test product(s); or history of hypersensitivity or allergic reactions to any of the study preparations as described in the investigator's brochure * any clinically significant central nervous system, cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal conditions * abnormal physical findings of clinical significance at the screening examination or baseline * history of orthostatic hypotension * clinically significant abnormal laboratory values * presence or history of allergies requiring acute or chronic treatment * 12 lead ecg abnormalities * major surgical interventions within 6 months of the study * has a positive pre-study hepatitis b surface antigen; positive hepatitis c (hcv) antibody or detectable hcv ribonucleic acid (rna); or positive hiv antibody result * use of prescription or non-prescription drugs * has a history of regular alcohol consumption * loss of 500 ml blood or more during the 3 month period before the study * people that follow vegetarian or vegan diet * symptoms of a significant somatic or mental illness in the four week period preceding drug administration * history of drug abuse or dependence within 12 months of the study * the subject has a positive pre-study alcohol or urine drug screen * concurrent participation in another drug or device research study or within 60 days of post participation in another drug or device study * considered by the investigator to be unsuitable candidate for this study

Keywords: gram negative bacteria infection
observational study of the use of octaplaslg®.

Conditions: Thrombotic Thrombocytopenic Purpura

Summary: this observational study enrolls patients who have received at least one infusion of octaplaslg®. octaplaslg® will be administered standard of care and observation occurs during the treatment and 24 hours after the end of treatment. characteristics of the use of octaplaslg®, tolerance criteria, and efficacy criteria will be collected.

prospective, non-interventional, multicentre study meeting a post-marketing need. the data will be collected in all patients who have received at least one infusion of octaplaslg®. the duration of follow-up is limited to the duration of treatment with octaplaslg® plus 24 h of monitoring after cessation of treatment. characteristics of the use of octaplaslg® (indication for the transfusion, degree of urgency, characteristics of plasma infusions, patient characteristics, number of iso-group and/or compatible units administered, tolerance criteria (adverse effects), and efficacy criteria (for patients with confirmed diagnosis of ttp--time to normalization of platelet count) will be collected.

Eligibility criteria:
inclusion criteria: 1. the patient is treated with octaplaslg® (receiving at least 1 unit of 200 ml octaplaslg®) 2. in accordance with reference methodology mr-003, the patient of legal age must be individually informed through an information sheet, and must not oppose participating in this non-interventional study (with no collection of consent). if the patient is unable to receive the information and express any opposition, family members or the trusted person receive the information and must not oppose the collection of data\*. for minor patients, one of the holders of parental authority receive the information and must not oppose the collection of data. * however, the patient in question will be informed if his/her condition later allows. exclusion criteria: 1) patient's refusal to participate